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ABSTRACT 
The present study deals with the evaluation of potential effects of Eclipta alba (EA) in memory impairment of mice. Memory 
impairment was induced by scopolamine (3 mg/kg, i.p) in animals.  To assess learning and memory in mice Morris water maze 
test was employed. The acetylcholinestrase enzyme (AChE) activity in brain was measured to evaluate the cent ral cholinergic 
activity. The levels of thiobarbituric acid-reactive species (TBARS) and reduced glutathione (GSH)in brain were estimated 
to assess the degree of oxidative stress. Scopolamine treatment produces significant impairment of learning and memory  in 
mice, as reflected by a significant decrease in MWM performance. Scopolamine also produced a significant enhancement of 
brain AChE activity and brain oxidative stress (increase in TBARS and decrease in GSH) levels.  EA (300 and 600 
mg/kg,oral) significantly prevented scopolamine-induced learning and memory deficits along with decrease of scopolamine-
induced rise in brain AChE activity and brain oxidative stress levels.  It may be concluded that Eclipta alba has significant 
protective action against scopolamine induced memory deficits in mice that can be attributed to its anti AChE and anti oxidant 
actions.  
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INTRODUCTION 
Alzheimer’s disease (AD) a neurodegenerative 
disorder of the elderly is a leading cause of dementia 
in developed countries. AD is a progressive, 
degenerative disease characterized by memory loss, 
language deterioration, poor judgment, impaired 
visuospatial skills, etc. Dysfunction of cholinergic 
neurotransmission in the brain contributes to the 
salient cognitive decline in AD. Loss of cholinergic 
cells, particularly in the basal forebrain, is 
accompanied by loss of the neurotransmitter 
acetylcholine.
1
 Pathologically, dementia in AD patients 
is caused by at least two distinct characteristic events. 
Deposition of the amyloid beta (Ab) peptide in the 
extracellular space and formation of intra-neuronal 
tangle owing to hyperphosphorylation of axonal Tau 
protein. Although deposition of Ab peptide and 
associated reactive oxygen species mediated neuronal 
damage is one of the major hallmarks of AD, the exact 
sequence of neuronal loss, synaptic dysfunction, and 
biochemical cascade of events therein are still 
unknown.
2
 The common symptoms of AD, such as 
loss of memory and tremor, have been recognized as 
a feature of increasing age for a long time and are 
acknowledged in many traditional medical systems.
3
 
AD   has affected more than 37 million worldwide and 
the economic burden in US alone is estimated to be 
around $100 billion .
4 
Since no cure for patients with AD is currently 
available, symptomatic treatment for AD focuses on the 
restoration of cholinergic function. One of the most 
accepted strategies in AD treatment is the use of 
cholinesterase inhibitors. Their clinical efficacy is 
thought to result from prolonging the half-life of 
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acetylcholine (Ach) through inhibition of 
acetylcholinestrase enzyme (AChE). 
5
 Rivastigmine, 
galantamine and donepezil are some of the AChE inhibitors 
which are main stay of treatment of cognitive deficit in AD. 
Memantine a NMDA receptor antagonist is another drug 
being used clinically. However these limited therapeutic 
modalities provide only symptomatic relief and are 
associated with number of undesirable side effects. So 
there is a need for the agent that not only will provide 
symptomatic relief but also halt the progression of the 
disease. Recently scientists have directed their focus 
towards herbal products as a source of treatment.
 
Several 
herbal drugs with antioxidant properties have been 
reported to have beneficial effects in AD. Clinical 
studies in AD patients have already shown that Ginko 
biloba is as effective as donepezil in improving 
dementia. 
6,7
 Although the mechanisms of the ant 
amnesic effects of most herbal extracts and constituents 
are not yet fully understood, one or more of the 
components could be responsible for the activation of 
the central ACh function through the inhibition of AChE 
and activation of ACh synthesis.
8
 Recent studies have 
pointed out that AD is associated with inflammatory 
processes. Reactive oxidative species (ROS) are able to 
damage cellular constituents and act as secondary 
messenger in inflammation. The use of antioxidants may 
be useful in the treatment of AD.
9 
Eclipta alba (L.)  Hassk. Family-Asteraceae has been 
mentioned in ancient texts to be a nervine tonic. 
10,11,12
 in 
addition to possessing hepato protective, hair growth 
promoting and anti-aging properties. A Small much-
branched annual herb with white flower heads, which is 
found in most situations throughout India ascending up 
to 600 feet on the hills.Commonly,it is Known as ‘white 
bhringraj’ when in flower and as ‘black bhringraj’when 
in fruit.
13
 The plant is reported to contain the 
phytoconstituents eclalbatin ,alphaamyrin, ursolic acid, 
oleanolic acid eclipta saponin,daucosterol,stigmasterol-
3-O-glucoside and coumestans (wedelolactone  and  
demethylwedelolactone) as main active principles.
14
A 
number of herbal preparations comprising of Eclipta 
alba are available for treatment of jaundice and viral 
hepatitis.
15,16,17 
In view of the above observations, we have selected the 
Eclipta Alba to explore its role in the treatment of AD. 
Exploring ameliorative potential and possible 
mechanism of Eclipta Alba in AD will open up new 
avenues in the drug therapy of this neurodegenerative 
disorder.  
Scopolamine has been used to induce experimental 
models of AD.
18,19
 Scopolamine significantly increases 
AChE and malondialdehyde (MDA) levels in the cortex 
and hippocampus.
20,21
 and has been used to screen 
antiamnesic drugs for the age-related CNS dysfunction. 
The elevation of brain oxidative status after 
administration of amnesic doses of scopolamine further 
substantiates the value of scopolamine-induced amnesia 
as an animal model to test for drugs with potential 
therapeutic benefits in dementia.
22
 To assess the 
antiamnesic effects of EA in mice, we evaluated the 
effect of EA on scopolamine-induced learning and 
memory deficits in the Morris water maze test. This 
study also evaluated the effect of EA on the biochemical 
parameters like AChE, TBARS and GSH activity in the 
brains of mice with scopolamine-induced dementia. 
MATERIALS AND METHODS 
Animals 
Swiss albino mice of either sex weighing 25±2g were 
employed in present study. The animals were housed in 
the departmental animal house and were exposed to 
12hr light and dark cycle. Before experiments the 
animals were acclimatize to the laboratory conditions. 
The experimental protocol was duly approved by the 
institutional animal ethical committee and care of the 
animals was carried out as per the guidelines of 
CPCSEA. 
Drugs and Chemicals 
Memantine (Almenta®,5mg/tablet, Sun Pharmaceutical 
Ltd, Mumbai, India), suspended in tween 80, were given 
orally and used as reference standard drugs in this study. 
Scopolamine was purchased from sigma-Aldrich (MO, 
USA). The dose of drugs and chemicals were selected 
based on previous literature report. All chemicals of 
analytical grade were used in the study. 
Preparation of Aqueous extract of Eclipta alba  
The plant drug was collected from the local market and 
authenticated by department of Pharmacognosy. The 
drug was coarsely powdered. The powdered plant 
material was then subjected to extraction with water by 
decoction for 18 h in Soxhlet’s extractor, to obtain the 
aqueous extracts. The yield of aqueous extract (Aq. 
Ext.) was found to be 31.44% (w/w). Preliminary 
photochemical investigations of the extract revealed 
presence of saponins, tannins, carbohydrates and 
phenolic compounds.  
Experimental design 
Mice were randomly allotted to groups of 6 animals 
each and treatment was carried out as outlined below:  
Group I (Vehicle control): Vehicle control group were 
treated with 1% tween 80 (p.o) 30 min before 
acquisition trials for four consecutive days and 30 min 
before retrieval trial (on day 5).  
Group II (amnesic control): Amnesic control group were 
treated with 3mg/kg Scopolamine intra-peritoneal 30 
min before acquisition trial conducted from day 1 to day 
4 and then vehicle only 30 min prior to retrieval trial 
conducted on day 5. 
Group III (Standard Treated Group):  this group was 
treated with 3mg/kg scopolamine and 
Memantine10mg/kg/day 30 min before acquisition trial 
conducted from day 1 to day 4 and then vehicle only 30 
min prior to retrieval trial conducted on day 5. 
Group IV (Test dose 1 treated group): this group was 
treated with 3mg/kg scopolamine and extract of EA 
300mg/kg/day 30 min before acquisition trial conducted 
from day 1 to day 4 and then vehicle only 30 min prior 
to retrieval trial conducted on day 5. 
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Group V (Test dose 2 treated group): This group was 
treated with 3mg/kg scopolamine and extract of EA 
600mg/kg/day. 30 min before acquisition trial conducted 
from day 1 to day 4 and then vehicle only 30 min prior 
to retrieval trial conducted on day 5. 
Evaluation of Memory using Morris water Maze:  
Morris water maze was used to assess learning and 
memory in experimental mice A circular pool (140 cm 
in diameter, 50 cm high) was filled to depth of 30 cm 
with water at a temperature of 22 18  . The pool was 
divided into four quadrants of equal area, Q1, Q2, Q3, 
and Q4. A glass platform (20 cm in diameter) was 
placed 1 cm below the surface, midway between the 
center and rim of the pool in the quadrant (Q4). The 
mice were introduced into the pool in the Q4 quadrant, 
and an uninformed observer measured the time taken for 
it to find the escape platform. In the event the animal 
was unable to locate the hidden platform within 180 s it 
was gently guided to it, kept for 20 s and then removed 
from the pool. The point of entry of the mice into the 
pool and the location of the escape platform remained 
unchanged throughout training session. Each animal was 
subjected to a daily session of three trials per day (with a 
rest period of 30–45 min inter trial periods) for five 
consecutive days Escape latency time (ELT) in seconds 
was recorded and day 4 ELT was taken as an index of 
acquisition whereas day 5 time spent in target quadrant 
(TSTQ) served as an index of retrieval or memory.
23 
 Brain Tissue Sampling and Preparation  
After completion of behavior tests, the animals were 
kept fasting for 12 hours. Blood samples were collected 
using the orbital sinus technique. Each animal was 
sacrificed and the whole brain of each animal was 
rapidly dissected, thoroughly washed with isotonic 
saline, dried and then weighed. The brain was 
homogenized with ice-cold 0.1M phosphate buffer (pH 
7.4, 10% (w/v). The homogenate was centrifuged at 
3000 rpm for 10 min at 4ºC. The supernatant (10%) was 
separated for biochemical analysis. 
Estimation of brain AChE activity 
The whole brain acetyl cholinesterase activity (AChE) 
was measured by the method Ellman et al. and Voss and 
Sachsse.
24,25
 The change in absorbance per min. of the 
sample was read spectrophotometrically sat 420nm.  
Estimation of thiobarbituric acid reactive substances 
The quantitative measurement of Thiobarbituric acid 
reactive substance (TBARS) an index of lipid per 
oxidation in brain was performed according to the 
method Ohkawa et al. The absorbance of developed 
pink color was measured spectrophotometrically at 
532nm. TBARS value was expressed as nano moles per 
mg of protein.
26 
Estimation of reduced glutathione 
The reduced glutathione content (GSH) in tissue was 
estimated using Beutler et al. Absorbance was noted 
spectrophotometrically at 412nm. All the values were 
expressed as micromoles of reduced glutathione per mg 
of protein.
27 
Statistical Analysis 
The results were expressed as mean ± standard deviation 
(S.D). The data obtained from various groups were 
statistically analysed using one-way ANOVA followed 
by Turkey’s multiple range test. A value of p<0.05 was 
considered to be statistically significant. 
RESULT 
Effect on ELT and time spent in target quadrant 
(TSTQ) using Morris water maze: 
Control untreated mice exhibit a significant fall in day4 
ELT as compared to its value on day1, reflecting 
acquisition (learning). Further significantly more time 
was spent in the target quadrant (Q4) in search of the 
missing platform as compare to the total time in the 
other quadrant (Q1, Q2, and Q3) during retrieval trial on 
5
th
 day, signifying memory or retrieval. Administration 
of scopolamine (3mg/kg) significantly prevented the 
diminish in day4 ELT as compared to the vehicle 
control group and markedly diminished TSTQ (Q4)  in 
search of missing platform during the retrieval trial, 
reflecting impairment of both learning as well as 
memory. Administration of Memantine10mg/kg/day to 
scopolamine-treated animals significantly attenuated day 
4 rise in the ELT as well as day 5
th
 decrease in TSTQ 
(P<0.05). Treatment with EA (300and600mg/kg) 
significantly decreased day4 ELT and increased day 5
th
 
TSTQ (P<0.05) in dose dependent manner, reflecting 
reversal of scopolamine-induced memory deficits 
[Figure 1]. 
Effect on Brain AChE Activity 
Scopolamine administration significantly, increase the 
brain AChE activity (µmol/min/mg protein) on 15
th
 day 
as compared to the control group (p<0.05). Treatment of 
EA (300 and 600 mg/kg) significantly decreased AChE 
activity when compared to the scopolamine (amnesic 
control) group (p<0.05). Memantine also significantly 
decreased AChE activity when compare to the 
scopolamine (amnesic control) group (p<0.05).Figure 2.
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Figure 1: Effect of EA 300mg/kg, 600mg/kg on total time spent in the target quadrant in seconds (TSTQ) using water 
maze test. a = p<0.05 Vs time in other quadrant in control group. b = p<0.05 Vs time spent in target quadrant in vehicle 
group. c = p<0.05 Vs time spent in target quadrant in amnesic control group. d= p<0.05 Vs time spent in target 
quadrant in amnesic control group. 
  
 
Figure 2: Effect of EA 300mg/kg, 600mg/kg on AChE in mice. a = p<0.01 brain AChE level of scopolamine treated 
group. b = p<0.05 Vs brain AChE level of scopolamine treated group. c = p<0.05 Vs brain AChE level of scopolamine 
treated group. 
 
Effect on Brain TBARS Activity 
Scopolamine treated group significantly increase the 
TBARS activity on 15
th
 day as compare to control 
group, reflecting enhanced oxidative stress (p<0.05). EA 
(300 and 600mg/kg) treated group significantly 
decreased the TBARS level (p<0.05) and abolished the 
scopolamine induced rise in brain oxidative stress level. 
Memantine also significantly decreased TBARS activity 
when compare to the scopolamine (amnesic control) 
group (p<0.05).Figure 3. 
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Figure 3: Effect of EA 300mg/kg, 600mg/kg on TBARS level in mice brain. a = p<0.01 brain TBARS level of 
scopolamine treated group. b = p<0.05 Vs brain TBARS level of scopolamine treated group. c = p<0.05 Vs brain 
TBARS level of scopolamine treated group. 
Effect on Brain GSH Activity 
Scopolamine treated group significantly reduce the GSH 
level on 15
th
 day as compare to control group (p<0.05) 
and reflecting enhanced oxidative stress. Treatment with 
EA (300 and 600mg/kg) significantly abolished the 
scopolamine induced rise in brain oxidative stress level 
(p<0.05) and significantly increase the level of GSH. 
The standard drug Memantine also reversed the effect of 
scopolamine on the GSH level. Figure 4. 
 
 
Figure 4: Effect of EA 300mg/kg, 600mg/kg on GSH level in mice brain. a = p<0.01 brain GSH level of scopolamine 
treated group. b = p<0.05 Vs brain GSH level of scopolamine treated group. c = p<0.05 Vs brain GSH level of 
scopolamine treated group. 
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DISCUSSION 
MWM test is one of the most widely accepted models to 
evaluate learning and memory of the animals. 
[23]
 A 
significant decrease in day 4 ELT of control animals 
during the ongoing acquisition trials indicate normal 
acquisition of memory and an increase in TSTQ in 
search of missing platform during retrieval trial indicate 
retrieval of memory. In the present study, scopolamine 
produced impairment of acquisition and retrieval of 
memory, as reflected by significant increase in day 4 
ELT and decrease in day 5 TSTQ, respectively. These 
results are consistent with earlier findings.
28
 In the 
present investigation, pretreatment of EA (300 and 
600mg/kg) abolished scopolamine-induced memory 
deficits. 
The central cholinergic system plays a major role in the 
process of learning and memory and has been carefully 
expressed over the last several years. The cholinergic 
cell bodies are destroyed by the disease process in AD 
patients, leading to a deficiency of the neurotransmitter 
Ach.
29
 several studies have revealed that blockade of 
ACh effects by muscarinic receptor antagonist 
scopolamine caused memory deficits in both normal and 
elderly groups.
30,31
 In our study, EA treatment 
significantly inhibited AChE activity in dose related 
manner. Therefore, it can be revealed that the 
antiamnesic effect of EA on scopolamine-induced 
impairment of learning and memory may be related to 
modification of cholinergic neuronal systems. Increased 
TBARS activity has been shown to be an important 
marker for in vivo lipid peroxidation in the learning and 
memory deficient mouse brains. In addition, it has been 
reported that scopolamine significantly increases 
TBARS activity in the hippocampus and frontal cortex. 
Levels of TBARS were elevated in all AD brain regions 
except the middle frontal gyrus. Elevated levels reached 
statistical significance in the hippocampus and pyriform 
cortex and marginal significance in the amygdala of AD 
subjects compared with age-matched controls.
32
 because 
thiobarbituric acid is highly reactive with non-lipid 
moieties as well as lipid per oxidation products; TBARS 
provide a non -specific marker of lipid peroxidation in 
AD brain
33
. In our study, EA treatment significantly 
inhibited TBARS activity in dose related manner. These 
findings are in line with earlier studies. This study 
further evaluated whether such impaired cognition by 
scopolamine is associated with altered oxidative stress 
indices. Scopolamine-treated mice had with reduced 
GSH activity.  Oxidative stress results from a marked 
imbalance between free radical production and 
elimination by antioxidant systems. Many studies have 
reported the strong positive correlation that memory 
impairments in the scopolamine-induced amnesic mice 
show with patterns of oxidative damage in patients with 
amnesic mild cognitive impairment.
20,22
 A clinical study 
have reported that oxidative stress is closely related in 
the pathogenesis of AD.
34
 GSH is the principal 
intracellular nonprotein thiol and plays a major role in 
the maintenance of the intracellular redox state. The 
level of GSH diminishes with an increase in the 
generation of free radicals.
35
 In the present study, GSH 
was estimated on the 15
th
 day after the first injection of 
scopolamine. Scopolamine-treated mice showed a 
significant decrease in the GSH in the brain compared to 
control values, indicating elevated oxidative stress. But 
EA treatment produced significant increase in the 
activities of GSH in mice brain. These observations 
suggest that EA produced significant antioxidant activity 
against scopolamine-induced oxidative stress. The 
effective antiamnesic effect of EA might result, in the 
reduction in oxidative stress and Inhibition of AChE 
activity which is the basis of AD management.
36
 Our 
study showed that EA can be effective neuroprotective 
agents which could be linked to the inhibition of both 
AChE and TBARS activity and increase in GSH activity 
in the brain of mice with scopolamine-induced amnesia. 
The antiAChE, antioxidant and antiamnesic effects of 
EA on scopolamine-induced cognitive impairments 
suggest that this may be the possible herbal drug for the 
treatment of AD. 
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